C84.74 Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb

Name of the Condition

• Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb (ICD-10 Code: C84.74)

Summary

Anaplastic large cell lymphoma (ALCL), ALK-negative, is a rare type of non-Hodgkin lymphoma that originates from T-cells or null cells. It is characterized by the presence of large, abnormal lymphoid cells and typically presents as a systemic disease, though cutaneous involvement may occur. The condition is aggressive and requires prompt evaluation and management.

Causes

The exact cause of ALK-negative ALCL is not fully understood. It is believed to involve genetic mutations in lymphoid cells, which lead to uncontrolled growth and accumulation. Environmental factors or chronic antigen stimulation may contribute to its development, though specific triggers remain unclear.

Risk Factors

• Age: More common in adults, particularly those over 60.
• Immunosuppression: Conditions or treatments that weaken the immune system.
• Genetic predispositions: Family history of lymphoma or related disorders.
• Prior lymphoid disorders: History of other lymphoid malignancies may increase risk.

Symptoms

• Swollen lymph nodes or masses in affected areas.
• Fever, night sweats, and unexplained weight loss (B symptoms).
• Skin lesions, rashes, or nodules (if cutaneous involvement is present).
• Fatigue, loss of appetite, and general malaise.
• Organ-specific symptoms (e.g., pain or swelling in the axilla or upper limb).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans), and biopsy of affected lymph nodes or tissues. Histopathological examination confirms the presence of large, abnormal cells, and immunohistochemistry or molecular testing is used to confirm ALK-negativity. Staging helps determine the extent of disease.

Treatment Options

Treatment typically includes systemic chemotherapy, often with regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Targeted therapies or immunotherapy may be considered for refractory or relapsed cases. Radiation therapy may be used for localized disease. Treatment plans are individualized based on disease stage and patient factors.

Prognosis and Follow-Up

Prognosis varies depending on disease stage, response to treatment, and patient health. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance is recommended due to the risk of relapse.

Complications

• Disease progression or transformation to a more aggressive form.
• Treatment-related side effects (e.g., infection, organ toxicity).
• Metastasis to other lymph nodes or organs.
• Chronic fatigue or reduced quality of life.

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known immunosuppressive factors (e.g., smoking, excessive alcohol).
• Follow recommended cancer screening guidelines.
• Manage stress and prioritize rest to support overall health.

When to Seek Professional Help

Seek medical attention if you experience persistent swollen lymph nodes, unexplained weight loss, fever, or other concerning symptoms. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

Document the specific site (axilla and upper limb lymph nodes) clearly in the medical record. Ensure ALK-negativity is confirmed and reported, as this distinguishes the condition from ALK-positive variants. Use additional codes for related symptoms or complications as needed, following coding guidelines for lymphoma and site-specific lymph node involvement.